Mustafa Ala, Obholz Jacob, Ghanim Mostafa, Congello Samuel
Internal Medicine, MercyOne North Iowa Medical Center, Mason City, USA.
Cardiology, MercyOne North Iowa Medical Center, Mason City, USA.
Cureus. 2022 Jan 28;14(1):e21691. doi: 10.7759/cureus.21691. eCollection 2022 Jan.
There are currently no definitive guidelines for the optimal management of clots in transit (CIT) due to a distinct lack of quality research to suggest a recommended therapy. The three main treatment modalities that are commonly utilized for pulmonary emboli (PE) (a sequela of CIT) are thrombolysis, pulmonary embolectomy, and anticoagulation alone. The current recommendation for severe PE with hemodynamic collapse is to consult cardiothoracic surgery for clot retrieval. One ongoing area of research involves the use of catheter-directed application of thrombolytic agents as it may have similar outcomes to the systemic application while minimizing the risk of bleeding events due to a lower dose of medication used. We report the case of a patient in whom, by taking advantage of an already placed peripherally inserted central catheter (PICC) line, tissue plasminogen activator (tPA) was successfully delivered at a localized site near the clot for active thrombolysis while only causing minimal adverse effects related to recent laminectomy/fasciectomy and foraminotomy compared to what may have been observed with systemic tPA administration.
目前,由于明显缺乏高质量研究来推荐一种治疗方法,对于漂浮血栓(CIT)的最佳管理尚无明确指南。肺栓塞(PE,CIT的一种后遗症)常用的三种主要治疗方式是溶栓、肺动脉血栓切除术和单纯抗凝。目前对于伴有血流动力学衰竭的严重PE的建议是咨询心胸外科进行血栓清除。一个正在进行的研究领域涉及导管定向应用溶栓药物,因为它可能具有与全身应用相似的效果,同时由于使用的药物剂量较低,可将出血事件的风险降至最低。我们报告了一例患者,通过利用已置入的外周静脉中心导管(PICC),组织纤溶酶原激活剂(tPA)成功地在血栓附近的局部部位给药,进行积极溶栓,与全身应用tPA相比,仅产生与近期椎板切除术/筋膜切除术和椎间孔切开术相关的最小不良反应。